Request Information
Request Information
Event Specialty: Robotics
Meeting
Johnson & Johnson’s Vice Chair of the Executive Committee and Chief Scientific Officer, Paul Stoffels, MD, visited Auris during a tour of health technology innovators in Silicon Valley.
Dr. Stoffels explained that collaborations in health technology are part of J&J’s “strategy to create a connected digital ecosystem using technology and data to improve patient outcomes.” J&J wants patients to be empowered enough to take control of their health, while providing surgeons with effective tools to deliver the best possible results.
While in Silicon Valley, Dr. Stoffels visited with several J&J collaborators, including Apple, Verily, and Auris. Auris, which joined the Johnson & Johnson Family of Companies earlier in 2019, is working with J&J to help make advances in combating lung cancer. Auris is also working with J&J to further innovation for other types of surgical procedures. While at Auris, Dr. Stoffels received hands-on demonstrations and obtained insights from our top researchers.
Dr. Stoffels believes that the advances in technology provided by these companies, coupled with J&J’s existing portfolio and expertise, will provide the foundation for the digital ecosystem the company hopes to create. This will ultimately lead to better results for patients and surgeons. Auris is proud to be a part of the team helping to achieve J&J’s goal of improving the health of everyone, everywhere.
Read more about Dr. Stoffels’ visits with healthcare innovatorsBronchoscopy Important Safety Statement:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology Important Safety Statement:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.